Abstract
Organ injury is caused by a variety of etiologies and can affect every organ of the human body. Generally, if the damage is substantial leading to the disruption of an organ’s architecture or function, the healing process eventually leads to organ fibrosis. Functioning cells and tissues are lost and replaced with the excessive accumulation of extracellular matrix. In an ideal situation damaged cells and tissues could be replaced with like-for-like types of cells to preserve organ function and prevent fibrosis formation. This process is called regeneration and is considered one of the holy grails in modern medicine.
Stem cells have the innate ability to differentiate into tissue specific cells and restore damaged cells under the right circumstances. The bone marrow niche is a natural source of endogenous stem cells and immunomodulatory cells that could be utilized to repair injury. This thesis describes the testing and translational development of a novel drug (MRG-001) and other pharmacological agents to repair organ injury, such as the kidney, liver and skin, through endogenous mobilization of bone marrow-derived stem cells and immunomodulatory cells in animals and humans.
Stem cells have the innate ability to differentiate into tissue specific cells and restore damaged cells under the right circumstances. The bone marrow niche is a natural source of endogenous stem cells and immunomodulatory cells that could be utilized to repair injury. This thesis describes the testing and translational development of a novel drug (MRG-001) and other pharmacological agents to repair organ injury, such as the kidney, liver and skin, through endogenous mobilization of bone marrow-derived stem cells and immunomodulatory cells in animals and humans.
Original language | English |
---|---|
Awarding Institution |
|
Supervisors/Advisors |
|
Award date | 5 Dec 2023 |
Place of Publication | Rotterdam |
Print ISBNs | 978-94-6361-943-1 |
Publication status | Published - 5 Dec 2023 |